While the primary endpoint in these CVOTs has been 3-point MACE, reductions in nonfatal/fatal MI and attenuated ischemic heart disease do not appear to be the primary driver of improved cardiovascular outcomes for SGLT2 inhibitors, but may play a more important role for the improved cardiovascular outcomes with GLP-1R agonists. The gene discussed is GLP1R; the disease is coronary artery disorder.